Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Methoxyflurane · Penthrane, DA-759

Small molecule · developed by Abbott

Approved FDA, May 1962

2 Registered trials

What is Methoxyflurane?

Methoxyflurane is an inhaled small-molecule anesthetic used as an analgesic in acute coronary syndrome and studied in unstable angina and myocardial infarction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Penthrane, DA-759, NSC-110432
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Abbott
In trials of: COLL
FDA status: Approved as Penthrane (May 4, 1962), NDA013056 · FDA label
UNII: 30905R8O7B

✅ FDA-approved uses

First aid to help prevent infection in minor cuts, scrapes, burns

From the indications section of the FDA label (version of Dec 26, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04442919	Phase 4	Unstable Angina	Completed	COLL
NCT04476173	Phase 3	ST Elevation Myocardial Infarction	Unknown	COLL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non ST Segment Elevation Acute Coronary SyndromeST Elevation Myocardial InfarctionUnstable Angina

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z